|Bid||1,725.40 x 0|
|Ask||1,725.40 x 0|
|Day's range||1,712.00 - 1,756.80|
|52-week range||1,215.83 - 1,817.00|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||17.16|
|Earnings date||27 Jul 2022|
|Forward dividend & yield||0.75 (4.24%)|
|Ex-dividend date||19 May 2022|
|1y target est||1,798.36|
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.